

## RESEARCH CURRICULUM VITAE

<b>Name: Dr Karl Gaffney</b>		<b>DOB: 6<sup>th</sup> April 1964</b>
<b>Present appointments:</b>		
Consultant Rheumatologist, Norfolk & Norwich University Hospital NHS Foundation Trust (NNUH - 1996-) Rheumatology Research Lead, NNUH (2013-) Honorary Reader, Norwich Medical School, UEA (2016-)		
<b>Address:</b>		
Department of Rheumatology East Block, Level 2 Norfolk and Norwich University Hospital NHS Foundation Trust Colney Lane, Norwich NR4 7UY		
<b>Telephone number:</b>	<b>Email address:</b>	
01603 289670	<a href="mailto:karl.gaffney@nnuh.nhs.uk">karl.gaffney@nnuh.nhs.uk</a>	
<b>Qualifications:</b>		
1998 MB. BCh. BAO (Hons), National University of Ireland 1988 FMGEMS 1990 MRCP 2000 FRCP (Ireland) 2004 FRCP (London)		
<b>Professional registration:</b>		
General Medical Council, 3622210, 1992 Medical Protection Society, 160680, 1988		
<b>Other/Previous Appointments:</b>		
<ul style="list-style-type: none"><li>• Chair, Research Leads, NNUH (2017-)</li><li>• Service Director for Rheumatology, NNUH (2008-15)</li><li>• Chair, Medical Advisory Board &amp; Trustee, National Ankylosing Spondylitis Society (NASS, 2009-) <a href="http://www.nass.co.uk">www.nass.co.uk</a></li><li>• Founder Member, Trustee &amp; Treasurer, The British Society for Spondyloarthritis (2014-) <a href="http://www.britspa.co.uk">www.britspa.co.uk</a></li><li>• Nominated Clinical Expert, The National Institute for Health &amp; Care Excellence for biological therapies in axial spondyloarthritis and ankylosing spondylitis (2005-) TA 143 (2008), TA 233 (2011), MTA 383 (2016), TA 350 (2016)</li></ul>		

- Chair, British Society for Rheumatology (BSR), Axial Spondyloarthritis Biologics Guidelines Committee (2012-)
- Invited Member, Assessment of Spondyloarthritis International Society (2012-)
- Member, Arthritis Research UK, Spondyloarthritis Clinical Studies Group (2015-)
- External Specialty Advisor for Rheumatology, London Deanery (2010-2014)
- Programme Director/Chair, Rheumatology Regional Training Committee, Eastern Deanery (2001-2012)
- Member, Rheumatology Specialty Advisory Committee, Royal College of Physicians London (2006-12)
- Director & Lecturer, MSc in Advanced Musculoskeletal Research and Practice UEA (2005-)
- BSR Council Member & Vice-Chair, External Relations Committee (2006-2010)
- Clinical Tutor & Associate Medical Director (Education), NNUH (1999-2005)
- ARC Clinical Research Fellow, The London Hospital Medical College (1993-5)

### **Research experience & personal grants awarded:**

- Research Lead Rheumatology (2013-) – Site Lead Investigator/UK Chief Investigator for 12 portfolio studies, largest recruiting centre to MSK portfolio studies EOE (2015-16) – actively recruiting to 7 CTIMPS
- BSRBRR – 776 patients recruited since 2002 – 2<sup>nd</sup> highest recruiting site nationally - >90% return rate – highest recruiter March-May 2017
- BSRBRAS - > 100 patients recruited
- Investigator-Initiated Research Grants (2012-):
  - ✓ ANSWERS : An open label, pilot, multicentre, step-down, randomised controlled trial to examine whether Etanercept 25mg once-weekly is effective in maintaining a clinical response in patients with Ankylosing Spondylitis who have responded to 50 mg once weekly (IRAS Ref 56082) (NIHR CRN Study ID: 9375). Pfizer 2012-£212,986
  - ✓ The prevalence of inflammatory back pain and spondyloarthritis in a primary care population in Norfolk: RH06S. Pfizer ICRP 2013- £52,341
  - ✓ Prevalence of axial SpA in patients presenting with anterior uveitis. AbbVie 2013 - £51,444
  - ✓ Research Capability Funding, NNUH 2015 - £20,000
  - ✓ Research Capability Funding, NNUH 2015 - £10,000
  - ✓ BRITSpA; Personally secured funding for a BRITSpA Research Fellow, Part-time Administrator, National Scientific Meeting, Travelling Fellowship via Educational Grants – AbbVie, UCB, Pfizer, Novartis 2014-2016. >£500,00 since 2014
- MD Supervisor; Drs Louise Hamilton (awarded July 2015) and Dr Mark Sykes (in preparation)
- Grant Assessor and Manuscript Reviewer (Arthritis Research UK, Arthritis & Rheumatism, Rheumatology, Arthritis Care & Research, Journal of Rheumatology, Annals of the Rheumatic Diseases, Clinical Rheumatology, Rheumfonds, Arthritis Ireland)
- Invited Session Chair, Meeting Convenor, Speaker – National & International Meetings – Copenhagen, Paris, Ghent, Madrid, Edinburgh, Birmingham, Leeds, Leicester, Manchester, Cheltenham, Aberdeen, Bristol, Birmingham, London, Belfast, Dublin, Liverpool, Cambridge (2011-6)

### **Research Collaboration/Studies In Progress**

- A randomised controlled trial to investigate the safety and efficacy of dose tapering of biologics in the treatment of axial spondyloarthritis (TOBIAS) – in conjunction with the Norwich CTU, National Ankylosing Spondylitis Society, British Society for Spondyloarthritis and British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBRAS, Prof Gary MacFarlane – University of Aberdeen) – NIHR HTA Expression of Interest – In preparation
- 2016 – GoPAST - Golimumab: A UK Two-part Observational Study Of Its Utilisation And Impact in Patients with Ankylosing Spondylitis– A multicentre UK study – MSD – Chief Investigator
- FOMAxS – Co-applicant - Fibromyalgia Optimal Management for patients with axial spondyloarthritis - Prof Gary MacFarlane – University of Aberdeen – Arthritis Research UK - £143,483.40 (Awarded December 2016)
- A study to determine if a patient self-completed questionnaire can predict the subsequent physician-verified diagnosis of axial spondyloarthritis - R&D Reference Number: 2014RH03L (63-04-14)
- Uveitis in axial SpA - collaboration with Scottish and Irish Registry for Ankylosing Spondylitis (SIRAS) and BSRBRAS – R&D Reference Number: 2014RH01L (45-03-14)
- MRC-Stratified Medicine Outline Application – axial spondyloarthritis – in conjunction with Dr Paul Bowness (University of Oxford) and Dr Raj Sengupta (Bath) - December 2016 submission
- Diffusion-weighted MRI in axial SpA – project in development – collaboration with Dr Donnie Cameron, UEA
- Evaluation of healthcare services for patients with axial SpA (in conjunction with BRITSpA, NASS and Dr Stefan Siebert – University of Glasgow) – manuscript in preparation
- The prevalence of axial SpA in patients with newly diagnosed colitis – Investigator-Initiated Study- AbbVie UK – grant proposal in preparation
- The prevalence of SI joint structural changes seen on CT pelvis in patients with colitis – AbbVie collaboration
- SERENA CAIN457F3402 (Novartis) - SEcukinumab REal-life use iN Approved Spondyloarthritis indications-Psoriatic Arthritis, Ankylosing Spondylitis – a multicenter international study of 5000 patients - Trial Design & Steering Committee Member - scheduled to begin in Jan 2017
- TNF survival and predictors of treatment response in axial SpA – a UK “real-life” experience – BRITSpA collaborative project (Manuscript in preparation)
- Molecular mechanisms and pathways of inflammatory and degenerative diseases: 07/H0706/81 - Professor Jagdeep Nanchahal, Kennedy Institute of Rheumatology, University of Oxford
- TRAIL1 trial of the use of pirfenidone in ILD associated with rheumatoid arthritis – Dr A Wilson
- Impact of diet on disease characteristics in axSpA – Prof. Aedin Cassidy, UEA
- Prevalence of chronic sacroillitis compatible with axSpA in patients with Crohn’s disease – collaborative project with AbbVie, UK - £222,350
- T2T axSpA – co-investigator
- Dynamism
- Fibromyalgia axSpA
- Serena
- Axis - Novartis

#### **Research training:**

- Arthritis Research Campaign Clinical Research Fellow, The Royal London Hospital Medical School (August 1993-December 1995).
- GCP Training – 28th July 2016

## Teaching/Training/Leadership Roles – Current

### NUUH/UEA

- Norwich Medical School - lecturer & personal tutor
- Host - Sixth form & student electives
- Organiser, Annual axial SpA Patient Information Day (2011-).
- Convenor, NNUH annual MSK update (2005-);
- Lecturer, MSc in Advanced MSK Research & Practice (UEA 2007-).
- Organiser, Norwich axial SpA Clinical Observation Programme (2008-).
- Invited Member, Scientific Steering Group, Quadram Institute, UEA (2016-)
- Invited Member CTRU Steering Group, UEA (2016-)
- Member, Trial Steering Committee methylphenidate in sarcoidosis - FAST-MP
- Established post-CCT rheumatology fellowship post in 2016

### National

- Chief Medical Advisor & Trustee NASS, (2010-)
- Nominated Clinical Expert, The National Institute for Health & Care Excellence - Biological therapies in axial spondyloarthritis and ankylosing spondylitis (2005-) TA 143 (2008), TA 233 (2011), TA 383 (2016), TA 350 (2016)
- Chair, British Society for Rheumatology (BSR), Axial Spondyloarthritis Biologics Guidelines Committee (2012-)
- Rheumatology External Advisor, London Deanery, 75 Trainees ARCP/PYAs (2011-)
- Consultant Mentor, BSR (2012-)
- Co-developed "Back in Focus"- [www.axialSpAbackinfocus.co.uk](http://www.axialSpAbackinfocus.co.uk) - an educational programme for UK healthcare professionals who are involved in the diagnosis and treatment of patients with axial spondyloarthritis (SpA -11 meetings 2012-2016 (526 delegates - rated good/excellent by 100%) - awarded an international "Communique award for Excellence in Meetings"-2014 & 2015.
- Co-developed "Meeting in a Box" in conjunction with NASS - a Primary Care Back Pain Educational Resource, launched at BSR AGM 2013 - 8 national seminars 2012-15 - 770 delegates - 100% rated good/excellent-now available on DVD – distributed to 36 countries
- Developed "Solving Spondyloarthritis" Podcast (March 2016) – trending at no. 1 on *itunes* Feb 2016 (Science & Medicine category) - 19,738 listens of over 90%, 55% UK based
- Developing an RCGP elearning educational programme on axial SpA (in conjunction with NASS & BRITSpA) – 2016 – launch date March 2017
- Developed "Back Pain Plus" – 2016 – an axial SpA awareness programme for ophthalmology, gastroenterology and dermatology
- Founder Member & Treasurer, BRITSpA (2014 -) – the only UK-based charity committed to advancing knowledge and treatment of spondyloarthritis – 146 members –hosted inaugural national scientific meeting 2015, established UK training fellowships & convenor of collaborative research projects - [www.britispa.co.uk](http://www.britispa.co.uk)
- Co-founder and chair, EOE SpA Academy 2017 – 48K

- BSR 2017 Symposia Abbvie, Novartis

My medical charities and educational role was acknowledged as an “Undercover Hero” in the Patient Choice Awards – House of Commons, November 2016

### International

- Invited Member, The Assessment of Spondyloarthritis International Society (ASAS) 2012-

## Publications

### Original Articles

Tumour Necrosis Factor inhibitor survival and predictors of response in axial spondyloarthritis - findings from a United Kingdom cohort. Yaha F, **Gaffney K**, Hamilton L, Lonsdale E, Leeder J, Brooksby A, Cavill C, Berry-Jenkins J, Boyle C, Bond D, Sengupta R. *Rheumatology* 2017; Submitted

Maintenance of low disease activity following dose-tapering TNF inhibitor dose tapering in Ankylosing Spondylitis. Steel L, Yates M, Hamilton L, **Gaffney K**. *J Rheumatology* 2017; In press

The prevalence of axial spondyloarthritis in patients with acute anterior uveitis – a cross-sectional cohort study with MRI verification. Sykes M, Hamilton L, Jones C, **Gaffney K**. *Ann Rheum Dis* 2016. Submitted

BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Hamilton L, Barkham N, Bhalla A, Brittain R, Jones G, Mackay K, Marshall D, Marzo-Ortega H, Murphy D, Riddell C, Sengupta R, Siebert S, Van Rossen L, Gaffney K. *Rheumatology* 2017; 56:313-6.

Comment on “Delay to Diagnosis in Axial SpA: Are We Improving in the UK?”  
Sykes M, Doll H, Sengupta R, **Gaffney K**. *Rheumatology* (Oxford) 2016; 55: 1707-8

Poor awareness of inflammatory back pain and axial spondyloarthritis amongst secondary care specialists. Mathieson HR, Merashli M, **Gaffney K**, Marzo-Ortega H. *Clin Rheumatol*. 2016 Oct; 35(10):2627-8.

Does the co-existence of acute anterior uveitis and chronic back pain prompt primary care physicians to consider a diagnosis of axial spondyloarthritis? Maxwell A, Yates M, Everden P, **Gaffney K**. *Ann Rheum Dis* 2016 Apr;75(4):e18. doi: 10.1136/annrheumdis-2015-208983. Epub 2016 Jan 20

The prevalence of axial spondyloarthritis in the UK: a cross-sectional cohort study. Hamilton L, Macgregor A, Toms A, Warmington V, Pinch E, **Gaffney K**. *BMC Musculoskeletal Disorders* (2015) 16:392-6.

Delay to Diagnosis in Axial SpA: Are We Improving in the UK?  
Sykes M, Doll H, Sengupta R, **Gaffney K**. *Rheumatology* (Oxford). 2015; 54(12):2283-4

Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Cortes A, Pulit SL, Leo PJ, Pointon JJ, Robinson PC, Weisman MH, Ward M, Gensler LS, Zhou X, Garchon HJ, Chiocchia G, Nossent J, Lie BA, Førre Ø, Tuomilehto J, Laiho K, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, Appleton L, Farrah C, Lau J, Haroon N, Mulero J, Blanco FJ, Gonzalez-Gay MA, Lopez-Larrea C, Bowness P, **Gaffney K**, Gaston H, Gladman DD, Rahman P, Maksymowych WP, Crusius JB, van der Horst-Bruinsma IE, Valle-Oñate R, Romero-Sánchez C, Hansen IM,

Pimentel-Santos FM, Inman RD, Martin J, Breban M, Wordsworth BP, Reveille JD, Evans DM, de Bakker PI, Brown MA. *Nat Commun* 2015 May 21;6:7146. DOI: 10.1038/ncomms8146

Correlation between clinical and MRI disease activity scores in axial spondyloarthritis. MacKay J, Aboelmagd S, **Gaffney K**. *Clin Rheumatol* 2015 Sep;34(9):1633-8

An open label, pilot, multi-centre, step-down, randomised controlled-trial to examine whether etanercept 25mg once weekly is effective in maintaining a clinical response in patients with ankylosing spondylitis who have responded to 50mg once weekly – The ANSWERS trial. Yates M, Elender F, Hamilton L, Dean L, Doll H, Thomas J, **Gaffney K**. *J Rheum* 2015 Jul;42(7):1177-85

Comment on: 'Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry' by Sorensen *et al*. Sykes M, Doll H, **Gaffney K**. *Ann Rheum Dis* 2014;1. doi:10.1136/annrheumdis-2014-205589

Prevalence of Inflammatory Back Pain in a UK Primary Care Population. Hamilton LE, MacGregor AJ, Warmington V, Pinch E, **Gaffney K**. *Rheumatology* 2014; 53: 161-164

Validation of a patient self-reported screening questionnaire for axial spondyloarthropathy in a UK population. Hamilton L, Newman D, Belkhir A, Toms A, MacGregor A, **Gaffney K**. *Spine (Phila Pa 1976)* 2013 ;38(6):502-6

Influences of Inflammatory Polyarthritis on Quantitative Heel Ultrasound Measurements. SR Pye, T Marshall, **K Gaffney**, R Luben, KT Khaw, AJ Silman, DPM Symmons, TW O'Neill. *BMC Musculoskeletal Disorders* 2012; 13:133

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility Evans DM, Spencer CC, **Gaffney K** et al. Erratum in: *Nat Genet.* 2011 Sep; 43(9):919.

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S, Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, Weisman MH, Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowych W, Gladman D, Rahman P; Spondyloarthritis Research Consortium of Canada (SPARCC)., Morgan A, Marzo-Ortega H, Bowness P, **Gaffney K**, Gaston JS, Smith M, Bruges-Armas J, Couto AR, Sorrentino R, Paladini F, Ferreira MA, Xu H, Liu Y, Jiang L, Lopez-Larrea C, Díaz-Peña R, López-Vázquez A, Zayats T, Band G, Bellenguez C, Blackburn H, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Freeman C, Gillman M, Gray E, Gwilliam R, Hammond N, Hunt SE, Jankowski J, Jayakumar A, Langford C, Liddle J, Markus HS, Mathew CG, McCann OT, McCarthy MI, Palmer CN, Peltonen L, Plomin R, Potter SC, Rautanen A, Ravindrarajah R, Ricketts M, Samani N, Sawcer SJ, Strange A, Trembath RC, Viswanathan AC, Waller M, Weston P, Whittaker P, Widaa S, Wood NW, McVean G, Reveille JD, Wordsworth BP, Brown MA, Donnelly P. Australo-Anglo-American Spondyloarthritis Consortium (TASC).; Wellcome Trust Case Control Consortium 2 (WTCCC2). *Nat Genet.* 2011 Jul 10;43(8):761-7.

Services for people with ankylosing spondylitis in the UK. Hamilton L, Gilbert A, Skerrett J, Dickinson S, **Gaffney K**. *Rheumatology* 2011; 50: 1991-8.

Factors influencing recruitment to rheumatology. Watson P, **Gaffney K**. *Rheumatology* 2011; *Clinical Medicine* 2011; 11: 509-510.

Influence of arthritis and non-arthritis-related factors on areal bone mineral density (BMDa) in

women with longstanding inflammatory polyarthritis: a primary care-based inception cohort. Pye SR, Marshall T, **Gaffney K**, Silman AJ, Symmons DP, O'Neill TW. *BMC Musculoskelet Disord*. 2010 May 28; 11:106.

Comment on: Screening for MTB prior to anti-TNF therapy – an audit of impact of the BTS guidelines on rheumatology practice. JD Pradeep, GPR Clunie, **K Gaffney**, A Brooksby, NJ Innes, P Bradley, A Gulati. *Rheumatology* 2009; 48: 1332.

Screening for MTB prior to anti-TNF therapy – an audit of impact of the BTS guidelines on rheumatology practice. JD Pradeep, GPR Clunie, **K Gaffney**, A Brooksby, NJ Innes, P Bradley, A Gulati. *Rheumatology* 2009; 48: 195.

Switching anti-TNF therapy in ankylosing spondylitis. DJ Pradeep, AC Keat, **K Gaffney**, A Brooksby, J Leeder, C Harris. *Rheumatology* 2008; 47: 1726-7.

Recognition of Inflammatory Back Pain and Ankylosing Spondylitis in Primary Care. Jois RN, **Gaffney K**. *Rheumatology* 2008; 47: 1364-6.

The influence of biological therapy on return to work in people with work disability due to ankylosing spondylitis. AC Keat, **K Gaffney**, AK Gilbert, C Harris, J Leeder. *Rheumatology* 2008; 47: 481-3.

Physical therapy in anti-TNF treated-patients with ankylosing spondylitis. SG Dubey, J Leeder, **K Gaffney**. *Rheumatology* 2008; 47: 1100-1.

Rituximab therapy in patients with resistant rheumatoid arthritis: real life experience. RN Jois, A Masding, M Somerville, **K Gaffney**, DGI Scott. *Rheumatology* 2007;46: 980-2

Demographic and Environmental Factors in a Wegener's Granulomatosis Cluster. J Lee, T Attygalle, **K Gaffney**, DGI Scott. *Ann Rheum Dis* 2007; 66: 278-9.

Patient Satisfaction With Rheumatology Practitioner Clinics: Can We Achieve Concordance by Meeting Patients' Information Needs and Encouraging Participatory Decision Making? AYN Lim, C Ellis, A Brooksby, **K Gaffney**. *Ann Acad Med (Singapore)* 2007; 36(2): 110-4.

Low dose infliximab treatment for ankylosing spondylitis: clinically and cost effective. RN Jois, J Leeder, A Gibb, **K Gaffney**, A MacGregor, M Somerville, DGI Scott. *Rheumatology* 2006;45: 1566-9.

Prevalence and associated factors for falls in women with established inflammatory polyarthritis. Anna E Oswald, Stephen R Pye, Terence W O'Neill, Diane Bunn, **Karl Gaffney**, Tarnya Marshall, Alan J Silman, Deborah PM Symmons. *J Rheumatol* 2006; 33(4): 690-4.

Methotrexate-related pancytopenia.: serious and under-reported? Our experience of 25 cases in 5 years: reply. A. Lim, **K Gaffney**, DGI Scott. *Rheumatology* 2006; 45: 363-4

Methotrexate-related pancytopenia.: serious and under-reported? Our experience of 25 cases in 5 years. A. Lim, **K Gaffney**, DGI Scott. *Rheumatology* 2005; 44: 1051-55

BSR Guidelines for Prescribing TNF Blockers in Adults with Ankylosing Spondylitis. Report of a working party of the British Society for Rheumatology. A Keat, N Barkham, A Bhalla, **K Gaffney**, H Marzo-Ortega, S Paul, F Rogers, M Somerville, R Sturrock, P Wordsworth. *Rheumatology* 2005; 44: 939-47.

Benchmarking – the five-year outcome of rheumatoid arthritis assessed using a pain score, the health assessment questionnaire and the short form 36 (SF 36) in a community-based sample. N Wiles, DGI Scott, EM Barrett, P Merry, E Arie, **K Gaffney**, AJ Silman, DPM

Symmons. *Ann Rheum Dis* 2001; 60: 956-61.

CD11b-positive blood lymphocytes correlate with disease activity in patients with rheumatoid arthritis. MG Macey, DA McCarthy, **K. Gaffney**, JD Perry, KA Brown, AC Newland. *Clin Exp Rheumatol* 1998; 16: 108-9.

Quantitative assessment of the rheumatoid synovial microvascular bed by gadolinium-DTPA-enhanced magnetic resonance imaging. **K Gaffney**, J Cookson, S Blades, A Coumbe, DR Blake. *Ann Rheum Dis* 1998; 57: 152-7.

Intra-articular pressure profile of the knee joint in a spectrum of inflammatory arthropathies. S Jawed, **K Gaffney**, DR Blake. *Ann Rheum Dis* 1997; 56: 686-9.

Xanthine Oxidase: four roles for the enzyme in rheumatoid pathology. Blake DR, Stevens CR, Sahinoglu T, Ellis G, **Gaffney K**, Edmonds S, Benbouetra M, Harrison R, Jawed S, Kanczler, Millar TM, Winyard PG, Zhand Z. *Biochem Soc Trans* 1997; 25(3): 812-6.

A modified form of low-density lipoprotein with increased electronegative charge is present in rheumatoid arthritis synovial fluid. L Dai, Z Zhang, PG Winyard, **K Gaffney**, H Jones, DR Blake, CJ Morris. *Free Radic Biol Med* 1997; 22: 705-10.

Activation of the transcription factor NF- $\kappa$ B in human-inflamed synovial tissue. R Marok, PG Winyard, A Coumbe, ML Kus, **K Gaffney**, S Blades, PI Mapp, CJ Morris, DR Blake, C Kaltschmidt, PA Baeuerle. *Arthritis Rheum* 1996; 39: 583-91.

Quantification of rheumatoid synovitis by magnetic resonance imaging. **K Gaffney**, J Cookson, DR Blake, A Coumbe, S Blades. *Arthritis Rheum* 1995; 38: 1610-17

Intra-articular pressure changes in rheumatoid and normal peripheral joints. **K Gaffney**, RB Williams, V Jolliffe, DR Blake. *Ann Rheum Dis* 1995; 54: 670-673.

Intra-articular triamcinolone hexacetonide in knee osteoarthritis: Factors influencing the clinical response. **K Gaffney**, J Ledingham, JD Perry. *Ann Rheum Dis* 1995; 54: 379-381.

Detection and investigation of the molecular nature of low-molecular-mass copper ions in isolated rheumatoid knee-joint synovial fluid. D Naughton, J Knappitt, K Fairburn, **K Gaffney**, DR Blake, Grootveld M. *FEBS Letters* 1995; 361: 167-172.

Mucocutaneous criteria for the diagnosis of Behcet's disease: an analysis of clinicopathological data from multiple international centers. JL Jorizzo, JL Abernethy, WL White, HC Mangelsdorf, CC Zouboulis, R Sarica, **K Gaffney**, C Mat, H Yazici, et al. *J Am Acad Derm* 1995, 32: 968-976.

Elevated lipoprotein (A) in carotid-artery atherosclerosis is unrelated to restenosis after endarterectomy. J Stinson, G D'Arcy, T Cooke, MP Colgan, M Hall, J Tyrell, **K Gaffney**, M Grouden, DJ Moore, G Shanik, J Feely. *J Vasc Surg* 1995; 29: 23-27.

Neutrophil Collagenase in sputum from patients with cystic fibrosis. C Power, CM O'Connor, D McFarlane, S O'Mahony, **K Gaffney**, J Hayes, MX FitzGerald. *Am J Resp Crit Care Med* 1994; 150: 818-822.

$\alpha$ 1-Proteinase Inhibitor, Elastase activity and lung disease severity in cystic fibrosis. CM O'Connor, **K Gaffney**, J Keane, A Southey, N Byrne, S O'Mahony, MX FitzGerald. *Am Rev Resp Dis* 1993; 148: 1665-70.

The Impact of HIV Disease on an Irish Prison Population. M Murphy, **K Gaffney**, O Carey, E Dooley, FM Mulcahy. *Int J of STD and AIDS* 1992; 3: 426-429.

Phlebotomy practice/needle stick injuries/hepatitis B status among interns in a Dublin



hospital. **K Gaffney**, M Murphy, F Mulcahy. *Ir Med J* 1992; 85: 102-104.

## Editorials

The Clinical utility of HLA B27 in axial spondyloarthritis. Lim E, Sengupta R, **Gaffney K**. *Rheumatology* 2017: In press.

Should axial spondyloarthritis without radiographic change be treated with anti-TNF agents? Keat A, Bennett AN, **Gaffney K**, Marzo-Ortega H, Sengupta H, Siebert S, Everiss T. *Rheumatology Int* 2017; 37:327-36.

Should axial spondyloarthritis without radiographic change be treated with anti-TNF agents? Keat A, Bennett AN, **Gaffney K**, Marzo-Ortega H, Sengupta H, Siebert S, Everiss T. *Rheumatology Int* 2017; DOI 10.1007/s00296-016-3635-8. [Epub ahead of print] Review. PMID: 28035438

Do low-dose anti-TNF regimens have a role in patients with Ankylosing Spondylitis. Yates M, Keat A, **Gaffney K**. *Rheumatology* 2016; 55: 769-72.

Expanding the spectrum of inflammatory spinal disease. AS it was, as it is now. Isdale A, Keat A, Barkham N, Bennett A, **Gaffney K**, Marzo-Ortega H, Sengupta R. *Rheumatology* 2013;52:2103-5.

Improving the Treatment of Ankylosing Spondylitis in the UK. Keat A, **Gaffney K**, Cornell T, MacKay K, Marzo-Ortega H, Skerrett J, Van-Rossen L, Wordsworth P. *Rheumatology* 2011; 50: 1936-9.

Predicting Outcomes in Ankylosing Spondylitis. J. Pradeep, A. Keat, **K. Gaffney**. *Rheumatology* 2008; 47: 942-5.

Anti-tumour necrosis factor therapy for ankylosing spondylitis – unresolved issues. R Jois, **K Gaffney**, A. Keat. *Rheumatology* 2007; 46: 899-901.

Early Rheumatoid Arthritis – the changing senario. RN Jois, **K Gaffney**. *J Rheumatology Occupational Therapy* 2007; 21: 6-8.

Early Rheumatoid Arthritis: approach to management. S Dubey, **K Gaffney**. *Clinical Medicine* 2005; 5: 211-3.

Azathioprine and Cyclophosphamide in the management of rheumatoid arthritis. **K Gaffney**, DGI Scott. *Br J Rheumatol* 1998; 37: 824-36.

The influence of intra-articular pressure changes on inflammatory arthritis. **K. Gaffney**, DR Blake. *Rheumatology in Europe* 1997; 26: 112-3.

Pressure and vascular changes in mobile joints: Implications for inflammatory joint disease. **K Gaffney**, SE Edmonds, CR Stevens, DR Blake. *Scand J Rheumatol* 1995; 23: 17-22.

Hypoxia and the rheumatoid joint: Immunological and therapeutic implications. SE Edmonds, G Ellis, **K Gaffney**, J Archer, DR Blake. *Scand J Rheumatol* 1995; 23: 151-156.

## Case Reports

Sustained remission of type I diabetes following rituximab therapy. Robinson A, **Gaffney K**.

*Rheumatology* 2016: Submitted

Large vessel vasculitis ; a rare but preventable cause of stroke. H Pathak, CY Yong, **K Gaffney**. *Indian J Rheumatol* March 17, 2017, IP: 64.233.173.12

Delayed presentation of Wegener's granulomatosis with pancreatic involvement. L. Hamilton, **K. Gaffney**, Andreou A, Saada J. *International Journal of Rheumatic Diseases* 2011; 14: 54-55.

An unusual case of chest pain. N Hassan, **K Gaffney**. *BMJ* 2008; 337: a898

Like father, like son. J Lee, P Merry, Ball R, **K. Gaffney**. *Ann Rheum Dis* 2007; 66: 1686-7

Spontaneous remission in Wegner's Granulomatosis. J Thomas, **K Gaffney**. *Scand J Rheumatol* 2007; 36: 324-6.

Methotrexate associated lymphoproliferative disorder masquerading as interstitial lung disease. R Jois, **K Gaffney**, P Cane, A Nicholson, A Wotherspoon. *Histopathology* 2007; 51:709-12

Juvenile onset spondylodiscitis - magnetic resonance imaging changes with Infliximab. A Lim, **K Gaffney**, T Marshall. *Rheumatology* 2004; 43:1456-8

Chronic Periaortitis, Idiopathic retroperitoneal fibrosis, Inflammatory aneurysm of abdominal aorta. RN Jois, **K Gaffney**, T Marshall, DGI Scott. *Rheumatology* 2004; 43:1441-6

A Pair of Buttocks. S Bawa, **K Gaffney**, TJ Marshall. *Rheumatology* 2004 ; 43:669-9

Intervertebral discitis presenting as oligoarthritis. T Marshall, **K Gaffney**. *Ann Rheum Dis* 2004; 63:634-5

Near fatal case of the dapsone hypersensitivity syndrome. KS Leslie, **K Gaffney**, CN Ross, S Ridley, TH Barker, J Garioch. *Clinical Dermatology* 2003; 28: 496-8

Rheumatoid Nodules. T Marshall, **K Gaffney**. *BMJ* 2002; 324: 858

A swollen leg unmasks longstanding SLE. SE Lane, **K Gaffney**, RY Ball, .M Marshall. *Lupus* 2001; 10: 4-8.

Ear, ear, what's going on in Norfolk. E Clarke, **K Gaffney**, P Merry, D. O'Gradaigh, D.Scott. *Ann Rheum Dis* 1999: 58; 660.

Unusual and memorable. Periostitis and bone proliferation. D O'Gradaigh, C Blundell, T Marshall, **K Gaffney**, P Chapman. *Ann Rheum Dis* 1999: 58; 263.

Interosseous nerve entrapment syndromes complicating inflammatory arthritis. **K Gaffney**, V Jolliffe, P Merry. *Clin Exp Rheumatol* 1997; 15: 339-40.

ANCA-positive polyarthritis associated with minocycline therapy. **K Gaffney**, P Merry. *Br J Rheumatol* 1996; 35: 1327.

Amyloidosis Complicating Cystic Fibrosis. **K Gaffney**, D Gibbons, B Keogh, MX FitzGerald. *Thorax* 1993; 48: 949-50.

Eosinophilic Fasciitis: A good response with conservative treatment. **K Gaffney**, G Kearns, D Moraes, JF O'Dowd, EB Casey. *Ir J Med Sci* 1993; 162: 256-7.

**Book Chapters**

Spinal Pain. Hamilton L, **Gaffney K.** *Oxford Textbook of Rheumatology* 4<sup>th</sup> Edition; 87-91

**Signature:**        **KARL GAFFNEY**

**Date:** 25/11/2016